Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,012,378
  • Shares Outstanding, K 42,590
  • Annual Sales, $ 130 K
  • Annual Income, $ -245,870 K
  • 36-Month Beta 1.83
  • Price/Sales 10,138.34
  • Price/Cash Flow N/A
  • Price/Book 5.49

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.69 +7.59%
on 01/16/18
53.39 -7.92%
on 01/04/18
+2.55 (+5.47%)
since 12/19/17
3-Month
43.14 +13.95%
on 12/18/17
54.35 -9.56%
on 12/04/17
-2.35 (-4.56%)
since 10/19/17
52-Week
43.14 +13.95%
on 12/18/17
91.35 -46.19%
on 03/02/17
-20.70 (-29.63%)
since 01/19/17

Most Recent Stories

More News
Anokion Announces Appointment of Dr. John Hohneker as Chief Executive Officer

Anokion, a privately held biopharmaceutical company developing novel tolerance-inducing therapeutics for autoimmune diseases, today announced the appointment of John Hohneker, M.D., as president...

RARE : 49.16 (+4.04%)
DMTX : 5.95 (-0.42%)
Ultragenyx Announces Interim Data from Early Stage Study

Ultragenyx (RARE) announces data from phase I/II study on its AAV gene therapy candidate, DTX301, demonstrating normalization of ureagenesis in patients with ornithine transcarbamylase deficiency.

CLDX : 2.76 (+0.73%)
CATB : 1.53 (unch)
RARE : 49.16 (+4.04%)
ANTH : 1.28 (-0.78%)
Newman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc. - RARE

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ:RARE) into...

RARE : 49.16 (+4.04%)
Interesting RARE Put And Call Options For August 17th

Investors in Ultragenyx Pharmaceutical Inc saw new options begin trading this week, for the August 17th expiration. One of the key data points that goes into the price an option buyer is willing to pay,...

RARE : 49.16 (+4.04%)
Ultragenyx to Present at J.P. Morgan Healthcare Conference

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D.,...

RARE : 49.16 (+4.04%)
JPM : 113.01 (-0.22%)
Ultragenyx Sells Priority Review Voucher for $130 million

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has entered into a definitive...

RARE : 49.16 (+4.04%)
NVS : 86.94 (+0.61%)
Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion for the Treatment of X-Linked Hypophosphatemia in Children

If approved, burosumab would be the first targeted disease-modifying treatment for XLH

RARE : 49.16 (+4.04%)
Biotech Stock Roundup: FDA Nod for Amgen PCSK9 Inhibitor, Revance Up on RT002 Data

Data presentations and regulatory updates were the key highlights this week with companies like AbbVie (ABBV) and Clovis providing data on their pipeline candidates.

RARE : 49.16 (+4.04%)
CLVS : 56.76 (+1.59%)
ABBV : 104.64 (+0.80%)
REGN : 371.53 (+0.07%)
AMGN : 189.28 (+0.90%)
BIIB : 342.41 (-0.59%)
RVNC : 33.95 (+0.59%)
Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 Study of Burosumab (KRN23) in X-Linked Hypophosphatemia

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin)...

RARE : 49.16 (+4.04%)
First Week of January 2018 Options Trading For Ultragenyx Pharmaceutical (RARE)

Investors in Ultragenyx Pharmaceutical Inc saw new options begin trading this week, for the January 2018 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the RARE...

RARE : 49.16 (+4.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023)...

See More

Key Turning Points

2nd Resistance Point 50.85
1st Resistance Point 50.00
Last Price 49.16
1st Support Level 47.68
2nd Support Level 46.21

See More

52-Week High 91.35
Fibonacci 61.8% 72.93
Fibonacci 50% 67.24
Fibonacci 38.2% 61.56
Last Price 49.16
52-Week Low 43.14

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.